Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Oxford Biotherapeutics Ltd.

Headquarters: Abingdon, Oxford, United Kingdom
Year Founded: 2004
Status: Private

BioCentury | Dec 5, 2023
Management Tracks

Glucksmann at the helm at Sensorium

Plus: CEO, CMO out at Theseus and updates from Zenas, Nanoscope, Immunitas and more
BioCentury | Jan 7, 2021
Deals

Jan. 6 Quick Takes:  Ribometrix gets $25M up front in Genentech RNA deal; plus Dewpoint-Pfizer, Kite-Oxford BioTherapeutics, Illumina-Helix and more

Ribometrix, Genentech partner for RNA-targeting small moleculesRibometrix Inc. and the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) are partnering to develop small molecules against undisclosed
BioCentury | Jun 8, 2018
Tools & Techniques

NK cell check-in

How new NK cell targets could lead to more powerful checkpoint inhibitors
BioCentury | Mar 7, 2018
Company News

Management tracks: Alliance, Anika

BioCentury | Feb 3, 2017
Financial News

Oxford BioTherapeutics completes debt financing

BioCentury | Apr 18, 2016
Company News

Nerviano, Oxford BioTherapeutics deal

BioCentury | Aug 3, 2015
Company News

Invenra, Oxford BioTherapeutics deal

Items per page:
1 - 10 of 28
Username